@article{oai:niigata-u.repo.nii.ac.jp:00019365,
 author = {吉谷, 徳夫 and 山本, 泰明 and 倉田, 仁 and 東野, 昌彦 and 石井, 美和子 and 安田, 雅弘 and 五十嵐, 裕一 and 金子, 亨 and 倉林, 工 and 中村, 稔 and 風間, 芳樹 and 児玉, 省二 and 田中, 憲一},
 issue = {5},
 journal = {新潟医学会雑誌, 新潟医学会雑誌},
 month = {May},
 note = {Human chorionic gonadotropin (hCG) is the most useful as the tumor marker in trophoblastic disease. Recently, highly sensitive and specific assay for hCG anti hCG-β carboxyl terminal peptide antibody (hCG-CTP assay) was developed. The sensitivity of the hCG-CTP assay in serum and urine was 0.2miu/ml. Cross reactivity with LH was little observed. In this paper, we dealed with the application of the hCG-CTP assay in management of hydatidiform mole patient and the problem of the assay which was observation of cross reactivity with hCG-like substance (hCG-LS) in serum and urine of women with hypergonadotropinism. It was indicated that administration of gonadotropin-releasing hormone, Buserelin, was inhibited hCG-LS in serum and urine of choriocarcinoma patient with hypergonadal state after remission.},
 pages = {348--353},
 title = {3) 絨毛性疾患における腫瘍マーカー(シンポジウム 腫瘍マーカーの臨床的意義, 第485回新潟医学会)},
 volume = {108},
 year = {1994}
}